Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL

计划入组 80 人 · 首次发布于 2022 年 9 月 29 日

Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL

计划入组 35 人 · 首次发布于 2022 年 2 月 23 日

Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO)

计划入组 92 人 · 首次发布于 2018 年 11 月 23 日

BCP-088

BCP-401

BCP-1071

ALL ABOUT,INC.

Japan

ALL SAINTS HEALTHCARE

United States

All About Pediatrics, LLC

United States

FDA Approves Blinatumomab for Early-Stage CD19-Positive B-ALL

Repurposed Drugs Show Promise for Treating Aggressive Infant Leukemia in Preclinical Studies

Real-World Study Confirms Blinatumomab Effectiveness as Bridge to Transplant in B-Cell Precursor ALL